Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)

Bibliografiska uppgifter
Huvudupphovsmän: Morgensztern, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Talbot, D, Ong, TJ
Materialtyp: Conference item
Språk:English
Publicerad: Elsevier 2018
Beskrivning
Sammanfattning:

Liknande verk